PGT-A as an IVF Add-On: Evidence, Limitations and Questions for Vikaspuri Couples

Key Takeaways

• PGT-A screens chromosome numbers in sampled embryo cells; it does not improve an embryo.
• Routine PGT-A has not been shown to increase cumulative live birth chances for every IVF patient.
• Mosaic, abnormal or inconclusive results need careful explanation before decisions about embryos.
• Your age, embryo numbers, history and priorities should guide discussion, not an add-on package.

If you are searching for PGT A testing Vikaspuri, you may be wondering whether paying for embryo testing will make IVF more likely to work. That is a fair question. The answer depends on what outcome you measure and your individual situation.

PGT-A as an IVF Add-On: Evidence, Limitations and Questions for Vikaspuri Couples

At Pravi Global IVF, we encourage you to ask what a test can change before agreeing to it. PGT-A can help select embryos in some situations, but it cannot guarantee a baby or make every IVF cycle more effective.

You deserve a discussion about benefits, uncertainty and alternatives. “Available” does not mean “needed”.

What does PGT-A actually test?

Preimplantation genetic testing for aneuploidy, or PGT-A, checks whether sampled embryo cells have the expected number of chromosomes. An embryo with extra or missing chromosomes may not implant, may miscarry, or may sometimes lead to an affected pregnancy.

In current practice, a trained embryologist usually removes a few cells from the outer layer of a blastocyst, an embryo commonly reaching this stage around day five to seven. These cells mainly contribute to the placenta, rather than the baby itself.

The sample goes to a genetics laboratory. Embryos are usually frozen while results are awaited. If an embryo is selected for transfer, this generally happens in a later frozen embryo transfer cycle.

• Euploid: the sample has the expected chromosome number within the test’s limits.
• Aneuploid: the sample shows an extra or missing chromosome, or sometimes a chromosome segment.
• Mosaic: the result suggests a mixture of chromosome patterns in the sampled cells.
• No result: the laboratory could not obtain a clear answer.

PGT-A is different from PGT-M, used for certain known single-gene conditions, and PGT-SR, used for certain structural chromosome rearrangements. A family history of inherited disease may need genetic counselling and a different testing plan.

What does the evidence say?

Research does not support offering PGT-A routinely to every person having IVF as a proven way to improve cumulative live birth. This means the chance of a baby from all embryos generated by one egg retrieval, not just one selected transfer.

Some studies and selected patient groups show better outcomes per transfer or fewer miscarriages after transfer of a euploid embryo. However, these figures do not include everyone who began treatment but had no embryo considered suitable for transfer.

For example, consider someone with two blastocysts. Testing may help decide which to transfer first, but it may also leave neither recommended for transfer. PGT-A does not create additional embryos or repair chromosome changes.

Ask your doctor to explain evidence relevant to your age and expected embryo numbers. A study involving patients with several blastocysts may not reflect your situation if you expect only one.

Who might consider a discussion?

A doctor may discuss PGT-A with increasing maternal age, when chromosome abnormalities become more common, particularly if several blastocysts are available. Even then, the possible benefit needs weighing against cost, embryo availability and laboratory limitations.

Repeated miscarriage or unsuccessful embryo transfers may prompt questions about testing. Neither automatically means PGT-A will help. Miscarriages and implantation difficulties can have causes that embryo chromosome screening does not address.

A doctor will decide whether to recommend testing after reviewing your history. You should have space to give informed consent or decline. Our IVF treatment information explains the wider treatment process.

Limitations worth understanding before consent

A biopsy examines a small sample, not every cell in an embryo. Sampling differences, technical factors and laboratory reporting thresholds can affect interpretation. False-positive and false-negative results are possible.

• Mosaic results need specialist review. Some mosaic embryos have resulted in healthy births, but outcomes and risks vary by finding.
• Biopsy is not risk-free. There is a small risk of damage; freezing and warming also carry a risk of embryo loss.
• Unclear results create further choices. Repeat biopsy may be discussed, but involves additional handling and may still not resolve uncertainty.
• Testing can narrow your options. Discuss reporting and embryo storage policies before signing consent.

A mosaic report should not be treated as identical to an aneuploid report. A genetic counsellor can explain the specific finding and whether transfer may be considered under the clinic’s policy.

PGT-A does not replace pregnancy screening or diagnostic testing. After conception, discuss prenatal options with your obstetrician; specialist advice is particularly relevant after mosaic embryo transfer.

PGT A testing Vikaspuri: questions to bring

When comparing PGT A testing Vikaspuri options, request a written explanation rather than only an add-on quotation. You can bring these questions on your phone:

• What is the reason for recommending this in our case?
• Are you discussing live birth per transfer or cumulative live birth per retrieval?
• What changes if we have only one or two blastocysts?
• Which laboratory tests the samples, and how does it report mosaic findings?
• What happens after an abnormal or inconclusive result?
• Which charges cover biopsy, testing, freezing, storage, counselling and later transfer?
• What would treatment without PGT-A look like?

Ask whether the estimate is per embryo or includes a set number. Do not assume medicines, repeat testing or frozen transfer are included. Comparing complete written estimates is more useful than comparing one headline charge.

Planning a visit from Vikaspuri

Many Vikaspuri residents use nearby Blue Line stations such as Janakpuri West or Janakpuri East. One option is the Blue Line to Rajouri Garden, then the Pink Line to Lajpat Nagar. Check current routes and interchange arrangements before leaving.

Lajpat Nagar metro is on the Violet and Pink lines. If travelling by car or cab, allow flexibility depending on traffic, especially around market hours. Ask about building access and parking beforehand.

Pravi Global IVF is at E-3, 3rd Floor, Lajpat Nagar 2, New Delhi. Bring previous IVF summaries, embryology reports and any genetic reports. For PGT A testing Vikaspuri enquiries, ask whether the first discussion needs both partners present.

Frequently Asked Questions

Is PGT-A compulsory with IVF?

No. It is an optional test. A doctor should explain any recommendation for your case and discuss proceeding without it.

Does a euploid result guarantee pregnancy?

No. Implantation also depends on other embryo factors, the uterus and additional clinical factors. A euploid embryo may not implant or may miscarry.

Is testing useful if we have one embryo?

There is no selection between embryos in that situation. Testing may provide information, but cost, uncertainty and the possibility of no transfer need careful discussion.

Can PGT-A check every inherited condition?

No. It mainly assesses chromosome number. A known inherited condition may require PGT-M or other targeted assessment after genetic counselling.

Can we discuss testing before starting injections?

Yes, and that is preferable. Discuss the biopsy plan, laboratory arrangements, consent, costs and possible results before treatment begins.

For an individual discussion, call Pravi Global IVF on +91 80091 50040 or book an appointment. Bring your reports and questions; you do not need to decide on an add-on before the consultation.